IMVT - NASDAQ
Immunovant, Inc.
$31.15
+1.2%Immunovant, Inc., a clinical-stage biopharmaceutical company, develops monoclonal antibodies for the treatment of autoimmune diseases. It develops batoclimab, a novel fully human monoclonal antibody that selectively binds to and inhibits the neonatal fragment crystallizable receptor, which is in Phase IIa clinical trials for the treatment of myasthenia gravis and thyroid eye disease, as well as completed initiation of Phase II clinical trials for the treatment of warm autoimmune hemolytic anemia. The company was incorporated in 2018 is headquartered in New York, New York. Immunovant, Inc. is a subsidiary of Roivant Sciences Ltd.
At a Glance
Live SnapshotImmunovant, Inc. Management Team
Dr. Eric Venker M.D., Pharm.D.
Chief Executive Officer & Director
Compensation
$55,000
Mr. Tiago M. Girao CPA
Chief Financial Officer
Mr. Christopher A. Van Tuyl Esq., J.D.
Chief Legal Officer & Corporate Secretary
Compensation
$549,038
Dr. Michael Geffner M.B.A., M.D., Ph.D.
Chief Medical Officer
Compensation
$804,015
Ms. Melanie Gloria B.S.N.
Chief Operating Officer
Compensation
$575,913
Dr. Jay S. Stout M.S., Ph.D.
Chief Technology Officer
Compensation
$683,490
Dr. Jay S. Stout Ph.D.
Chief Technology Officer
Compensation
$683,490
Dr. Frank M. Torti M.B.A., M.D.
Executive Chairperson of the Board
Compensation
$92,500
Ms. Christine Blodgett
Senior Vice President of Human Resources
Mr. Andy Deig
Senior Vice President of Strategic Finance
Mr. Andy Deig M.B.A.
Senior Vice President of Strategic Finance
Ms. Lauren Schrier M.B.A.
Vice President & Head of Global Medical Affairs
Immunovant, Inc. Insider Positioning
During the last 12 months, insiders have purchased $350.00M and sold $3.75M worth of IMVT shares, resulting in $346.25M of net buying activity.
3 Months
0
0.00
86.9K
2.43M
-2.4M
-$2.43M
3-6 Months
16.7M
350.00M
13.1K
349.07K
+349.7M
+$349.65M
6-9 Months
0
0.00
37.6K
833.00K
-833K
-$833K
9-12 Months
0
0.00
7.9K
140.38K
-140K
-$140K
Top Buyers
Roivant Sciences Ltd.
Director, 10 Percent Owner:
$350.00M
Top Sellers
Fromkin Andrew J.
Director
$823K
Girao Tiago
Officer: Chief Financial Officer
$763K
Stout Jay S
Officer: Chief Technology Officer
$528K
Gloria Melanie
Officer: Chief Operating Officer
$504K
Van Tuyl Christopher
Officer: Chief Legal Officer
$428K
Insider Activity Analysis
Net Insider Sentiment
Strong bullish signal with $346.25M net buying. Insiders are aggressively accumulating shares, suggesting significant confidence in future prospects.
Buy/Sell Ratio
Exceptional buy/sell ratio. Buying dramatically outweighs selling—one of the strongest possible insider signals.
Recent Trend (3 Months)
Heavy recent selling activity. Recent insider sales notably exceed purchases—may warrant investigation into company developments.
Insider Participation
5 insider sellers vs. 1 buyers. Widespread selling across multiple insiders may signal concerns.
SEC Filings
IMVT - Filing history and reports
| Filing Type | Filing Date | Period Ending | Fiscal Year | Actions |
|---|---|---|---|---|
DEF 14A DEF 14A 2025 N/A | July 09, 2025 | August 27, 2025 | 2025 | |
DEF 14A DEF 14A 2024 N/A | June 26, 2024 | August 12, 2024 | 2024 | |
DEF 14A DEF 14A 2023 N/A | June 26, 2023 | August 21, 2023 | 2023 | |
DEF 14A DEF 14A 2022 N/A | June 30, 2022 | March 31, 2022 | 2022 | |
DEF 14A DEF 14A 2021 N/A | August 12, 2021 | September 09, 2021 | 2021 | |
DEF 14A DEF 14A 2020 N/A | July 09, 2020 | August 19, 2020 | 2020 |
Research Paths
Snapshot
Start with context, operating signals, and key market metrics.
Value Model
Stress test fair value across bear, base, and bull assumptions.
Statements
Validate revenue quality, margins, and balance sheet durability.
Earnings Call
Read management commentary and compare it with reported outcomes.
Dividends
Check payout sustainability and long-term distribution behavior.
Analyst Expectations
Review consensus spread and where estimate risk is concentrated.